rs121434595, NRAS

N. diseases: 19
Disease: melanoma ×
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968 2014
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968 2014
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. 23414587 2013
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. 23414587 2013
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. 22962325 2012
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. 20179705 2010
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. 20130576 2010
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. 20130576 2010
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. 20179705 2010
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. 18390968 2008
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. 18390968 2008
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR Distinct sets of genetic alterations in melanoma. 16291983 2005
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR Distinct sets of genetic alterations in melanoma. 16291983 2005
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR Ras mutations in human melanoma: a marker of malignant progression. 8120410 1994
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR Ras mutations in human melanoma: a marker of malignant progression. 8120410 1994
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR N-ras mutations in human cutaneous melanoma from sun-exposed body sites. 2674680 1989
melanoma
CUI: C0025202
Disease: melanoma
0.700 CausalMutation CLINVAR N-ras mutations in human cutaneous melanoma from sun-exposed body sites. 2674680 1989